The US company is engaged in a strategic collaboration with the Johnson & Johnson unit Janssen Biotech to develop and commercialize its lead product candidate, LCAR-B38M/JNJ-4528.

This is an investigational BCMA-targeted CAR-T cell therapy for patients living with relapsed or refractory multiple myeloma. It is currently being studied in registrational clinical trials.